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Background: Hypertensive disorders in pregnancy are associated with systemic endothelial dysfunction leading to
impaired physiological vasodilation. Recent evidence has shown central aortic pressures obtained through pulse
wave analysis, at less than 14 weeks of gestation, to be predictive of pre-eclampsia. In light of this, we aimed to
evaluate the role of central aortic stiffness in the prediction and discrimination of hypertensive disorders in
pregnancy.
Methods: A cohort study of women with viable, singleton pregnancies at less than 14 weeks of amenorrhoea, and
without multiple pregnancies, autoimmune or renal disease, diagnosed with aneuploidy or fetal anomaly will be
recruited from a single maternity hospital and followed up till delivery and puerperium. A targeted sample size of
1000 eligible pregnant women will be enrolled into the study from antenatal clinics. Main exposure under study is
central aortic pulse pressure using radial pulse wave recording, and the outcomes under follow-up are gestational
hypertension and pre-eclampsia. Other measures include lifestyle factors such as smoking, physical exercise,
psychometric evaluations, vasoactive factors, uterine artery pulsatility index, height and weight measurements.
These measures will be repeated over 4 antenatal visits at 11-14, 18-22, 28-32 and above 34 weeks of gestation.
Double data entry will be performed on Microsoft Access, and analysis of data will include the use of random effect
models and receiver operating characteristic curves on Stata 11.2.
Discussion: The proposed study design will enable a longitudinal evaluation of the central aortic pressure changes
as a marker for vascular compliance during pregnancy. As measures are repeated over time, the timing and severity
of changes are detectable, and findings may yield important information on how aberrant vascular responses occur
and its role in the early detection and prediction of hypertensive disorders.
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Hypertensive disorders occur in 10–15% of pregnancies,
mainly with gestational hypertension at 10–12%, followed
by pre-eclampsia at 3–5% and severe pre-eclampsia at less
than 1% [1,2]. About 15% (ranged between 7 to 46%) of
women with gestational hypertension, may progress to pre-
eclampsia and 9% to severe diseases [3]. Unlike gestational
hypertension, preeclampsia is a multi-system disorder in-
volving both maternal and fetal manifestations [4,5].* Correspondence: Kenneth.Kwek.Y.C@kkh.com.sg
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reproduction in any medium, provided the orThe origin of pre-eclampsia is rooted in the pathological
development of placenta, of which is thought to be asso-
ciated with angiogenic imbalance [6,7]. Downregulation of
placental growth factor (PlGF) and upregulation of soluble
fms like Tyrosine Kinase-1 (sFlt-1) have been observed as
early as 8 – 10 weeks of amenorrhoea [8] and derangement
in these factors are associated with altered vascular endo-
thelial responses in women with pre-eclampsia [9-13]. The
relationship between endothelial function, PlGF and sFlt-1
appeared to be consistent [14], and subtle changes in the
endothelium have been proposed to occur from first
trimester onwards, prior to overt hypertension and
proteinuria [6,15].
In the pathological development of gestational hyper-
tension or pre-eclampsia, arterial stiffness or reduced
arterial compliance occurs with diffuse vasoconstriction. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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endothelial dysfunction [6,16]. This led to profound
changes in the haemodynamic measures such as the cen-
tral aortic and peripheral blood pressures. As suggested by
Cnossen et al in 2008, brachial blood pressures discrimin-
ate poorly in a spectrum of hypertensive disorders. By
contrast, central aortic pressures have been associated
with better predictive values compared to conventional
brachial blood pressures, and as early as less than 14 weeks
gestation using pulse wave analysis [17,18]. Moreover,
higher arterial stiffness is associated with preeclampsia
compared with gestational hypertension or those with
normal pregnancies [19].
It has been suggested that combined screening approaches
involving ultrasonographic and biochemical markers
from first to second trimester performed better than
single markers alone in terms of sensitivity and/or spe-
cificity [20,21]. In studies with concurrent use of first
trimester uterine artery pulsatility index (UAPI), bio-
chemical (PlGF or pregnancy associated plasma protein
A) and arterial blood pressure (mean arterial or central
augmentation index), there were good detection rate
and discriminatory power between variants of hyper-
tensive disorders (gestational hypertension, early and
late pre-eclampsia) [22-25]. The simultaneous use of
these markers holds promise for early detection of pre-
eclampsia as they are indicative of endothelial function
and cardiovascular risk.
Although there are evidence to suggest that central aor-
tic pressures are more robust than brachial blood pres-
sures in prediction of cardiovascular outcomes in the
general population [26-28], studies in pregnant women
are lacking in numbers and sample size (Table 1). Current
evidence points to the need for systematic measurements
of central aortic pressures across pregnancy trimesters till
the development of hypertension, and the adjustment for
potential confounders. Study findings may unravel how
the development of aortic stiffness in hypertensive disor-
ders in pregnancy occurs, and their potential value if any,
beyond brachial blood pressures in clinical application.
Study aims
This study aims to evaluate the role of central aortic
stiffness in prediction of hypertensive disorders in preg-
nancy. The specific objectives are:
1. To identify gestation specific factors associated with
central aortic stiffness as measured by central aortic
pulse pressure (CAPP).
2. To measure the association between central aortic
stiffness as quantified by CAPP and pregnancy
associated hypertensive disorders
3. To determine the predictive performance of CAPP,
sFlt-1 and PlGF, and UAPI measured at firsttrimester for early detection hypertensive disorder in
pregnancy
Methods
Study design and setting
A prospective cohort of 1000 pregnant women will be
recruited for follow-up till delivery and puerperium in
KK Women’s and Children’s Hospital, a maternity hos-
pital which handles an average of 12000 deliveries annu-
ally. This study has been approved by Institutional
Review Board in 2010. Written informed consent will be
obtained from all study participants.
Study population and sampling method
The study population will comprise mostly of Chinese,
Malay and Indian ethnicities following the make-up of
Singapore resident population [29]. Women with viable,
singleton pregnancies at less than 14 weeks of amenor-
rhoea will be recruited, and those with multiple preg-
nancies, autoimmune or renal disease, diagnosed with
aneuploidy or fetal anomaly will be excluded.
A convenient sampling of women seeking antenatal
care at the outpatient clinics will be screened for study
recruitment. Based on 80% eligibility and 50% participa-
tion rates, the target sample size of 1000 out of 2400
patients is attainable (Figure 1). The final sample size is
expected at 850 having accounted for 15% dropout rate.
Sample power calculation
Assuming a 10% difference in incidence of hypertensive
disorder between the lowest and highest quartiles of
central aortic pulse pressure, and a base incidence of 5%,
a total of 207 participants are required in each quartile
to achieve 80% power and at 5% alpha. The overall study
sample therefore is at 828 participants with complete
study follow-ups.
Recruitment strategies
Recruitment began in April 2011, at the antenatal spe-
cialist outpatient units and staffs at these units were
briefed on the project. At screening, basic demographic
factors such as education, employment and marital sta-
tus are collected. Women who are unsure about study
participation will be contacted within the week, and after
3 unsuccessful attempts of telephone contact within
2 weeks; patient will be deemed ‘uncontactable’. Women
who had consented into the study, and subsequently
miscarried or decided to deliver elsewhere will be con-
sidered as ‘ineligible’.
Study procedures
After written consent, the study participants will be
followed-up till the diagnosis of hypertensive disorder in
pregnancy (gestational hypertension or pre-eclampsia)
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CAPP = Central Aortic Pulse Pressure in mmHg, AI = Augmentation Index in%,
* = Median (Interquartile range).
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§ = Odds Ratio(95% confidence interval).
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posure of interest will be measured over 4 study visits at
11-14, 18-22, 28-32 and above 34 weeks of gestation.
Study follow-up for outcome ascertainment will con-
tinue till hospital discharge after delivery.
At study enrolment, baseline information on socio-
economic, personal medical and obstetric history will be
obtained through an interviewer administered question-
naire. Other measures involving lifestyle behaviours, psy-
chometric assessments and biophysical measures such as
anthropometry, UAPI and blood sample for vasoactive
factors (sFlt-1 and PlGF) will be done simultaneously at
the 4 study visits as mentioned above (Figure 2).
Central aortic pulse pressure measurement
Central aortic pressures are derived from radial pulse wave
analysis, obtained through a BProW device. It is a wrist
watch like instrument which utilizes applanation tonometry
on the radial pulse, developed by HealthStats, Singapore.
The study participants are required to abstain from coffee
intake for at least 0.5 hour, and prior to measurement,
they are to be seated comfortably and rested for at least
5 minutes in a quiet room. From the right upper arm,brachial blood pressures are repeated three times at inter-
vals of 30 – 60 seconds using an oscillometric device by
HealthStats (MC3100), whereby difference between each
measurement should not differ by more than 10 mmHg for
either systolic or diastolic pressures. After achieving a stable
reading, the systolic and diastolic averages will be used to
calibrate the radial pulse wave forms and continuous sam-
pling of the latter will ensue for 40-60 seconds.
Central aortic pulse pressure as a measure of arterial
stiffness is the difference in pressure between central aor-
tic systolic and brachial diastolic pressures in mmHg. This
measure is dependent on the use of radial pulse wave ana-
lysis to derive central aortic systolic pressure which has
shown good agreement with invasive measurements using
cardiac catheterization [30], and that diastolic pressure is
stable between central and peripheral (brachial) sites
[31,32]. An internal validation has been conducted for the
measurement of central aortic pulse pressure, and the co-
efficient of variation is at 1.9%.
Other measures
Questionnaires are employed to gather information per-
taining to socio-economic, lifestyle, sleep and maternal
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Figure 1 Target sample at antenatal outpatient clinics (study status as of November 2011).
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tured questionnaires were used to collect demographic
data on variables such as maternal and partner’s date of
birth, race, education, occupation, type of housing, house-
hold size and income; life style variables such as alcohol
and coffee intake, physical exercise and daily activities and
smoking habits; and lastly personal or family history of
gestational diabetes, hypertension or pre-eclampsia.
Validated self-administered questionnaires are used to
determine sleep and maternal coping in pregnancy. As-
sessment of sleeping habit are done through Pittsburgh
Sleep Quality Index [33]; and maternal coping during
pregnancy through psychometric assessments on maternal
stress, anxiety and depression scores using Stress Trait &
Anxiety Inventory [34], Perceived Stress Scale [35], Roesch
Questionnaire [36] and Edinburgh Postnatal Depression
Scale [37] respectively.
All self-administered questionnaires are available in
Chinese and Malay versions. These questionnaires are
translated forward and backward into English for all ex-
cept Stress Trait & Anxiety Inventory, as it is available inboth languages. Both interviewer and self-administered
questionnaires are administered by trained staffs that are
conversant in both English and Chinese or Malay.
Biophysical measurements including anthropometry,
ultrasound doppler (UAPI) and serum biomarkers for
sFlt-1 and PlGF are done by hospital nurses, sonographers
and laboratory technologists that are accredited to per-
form these procedures. Serum samples would be aliquoted
and stored in -80°C at the research laboratory.
Assessment of hypertensive disorder in pregnancy
The definitions of hypertensive disorder in pregnancy are
based on the criteria as specified by Working Group on
High Blood Pressure in Pregnancy [4,38]. Therefore, ges-
tational hypertension is defined as new onset of hyperten-
sion in pregnancy with brachial systolic pressure at
140 mmHg and above, or a diastolic pressure of 90 mmHg
or above on repeated measurements of more than 6 hours
interval within 1 week after 20 weeks gestation without
proteinuria. In pre-eclampsia however, the definition
includes both hypertension and proteinuria at above 0.3 g
Recruitment and consent 
taking
Study Procedures at each 
visit:
Radial pulse wave analysis
Questionnaires  (lifestyle, 
psychometric, sleep and 
past medical history)
Physical measurements 
(height, weight and blood 
pressures)
U/S doppler  (UAPI)
Blood sample 
(sFlt and PlGF )
Determine if patient is 
diagnosed with pregnancy 
associated hypertensive 
disorder from 2nd study 
visit onwards
Repeat Procedures at
11-14, 18-22, 28-32 and >34 
weeks of gestation
End of pregnancy or 





Figure 2 Flowchart for study procedures.
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on more than one occasion or ≥ 30 mg/dL protein in a
spot urine if a 24 hour urine protein collection cannot be
obtained). Outcome ascertainment will be done by trained
medical personnel based on the above criteria.
Data management
Data entry will be done by 2 independent research staff
in 2 separate access databases. Weekly entry of raw data
will be done to ensure timely clearance. At data verifica-
tion, databases will be locked and no entries are made
until all queries are resolved. Training and simulations
for data entry have been conducted for familiarization
purposes. Moreover, protocols for data entry, verification
and cleaning are provided to staff involved in data entry
and cleaning.
Statistical methods
At the end of data validation and cleaning, data will be
prepared for analysis through reduction of some variables
into fewer categories such as occupation and generation
of new variables such as body mass index. Data analysis
will be carried out using Stata version 11.2 (Statacorp,
College Station, Texas). Analysis will include distributionof sample characteristics in relation to gestational hyper-
tension and pre-eclampsia in proportions and central ten-
dencies; and their crude associations using mixed models
for correlated data.
Selection of potential risk factors will be based on bio-
logical plausibility and at a significance level of 0.2 for
subsequent modelling. Receiver Operator Characteristic
curves will be employed to assess the predictive capabil-
ities of tests. Sensitivity and likelihood ratios will be
reported based on 5% and 10% false positive rates. Miss-
ing data will be assessed for bias and depending on its
nature, sensitivity analysis or multiple imputation tech-
niques may be employed to deal with the loss of infor-
mation in the dataset.
Discussion
Recruitment of study participants begun in April 2011
and by November 2011, 366 eligible pregnant women
were screened and 192 (52.5%) had consented into the
study. The recruitment rate was slower than expected as
recruitment was temporally suspended from late August
2011 to end October due to staffing issues. During this
period, study follow-ups were on-going to minimize dis-
ruption to study flow. Recruitment resumed in early
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for eligible participants at antenatal outpatient clinics.
Amongst the 192 study participants, 84 (44%) were
Chinese, 60 (31%) Malays, 19 (10%) Indians and 29 (15.1%)
were of other ethnicities. The mean age was at 30 years
old, ranging from 19 to 44 years old. About 47 (25%)
received tertiary education, and 138 (73%) were employed
at the time of recruitment. Preliminary comparison bet-
ween those who consented and refused study participation
showed that age, education level and employment status
were similar. However, there were significant racial differ-
ences amongst those who refused participation, whereby
Indians tended to refuse participation (64.2%) and Malays
tended to participate (60.6%), p value = 0.036.
From literature review, elevations in central aortic pres-
sures (augmentation index, systolic and diastolic pres-
sures) are greatest amongst women with pre-eclampsia,
followed by gestational hypertension compared to women
with normal pregnancies [16,39-43]. Predictive perform-
ance using central aortic augmentation index measured at
11-14 weeks of amenorrhoea has 50-57% sensitivity in
detecting pre-eclampsia [17,18] as compared to 24-35%
for brachial systolic, diastolic and mean arterial blood
pressures [15].
Although current reports on these measures provide
valuable information about circulatory changes asso-
ciated with hypertension disorders in pregnancy, pres-
ently they do not infer central aortic pressures ability to
discriminate pre-eclampsia from gestational hyperten-
sion or normal pregnancies. The observed difference in
central aortic pressures may be flawed due to the cross-
sectional approach that utilized concurrent measure-
ment of central aortic pressures and pre-eclampsia [44].
It is therefore difficult to establish temporality i.e. eleva-
tion of central aortic pressures prior to pre-eclampsia.
Furthermore, there are limitations associated with in-
terpretation of these indices. Firstly, the validity of the
central aortic augmentation index is questionable as they
were derived from a generalized transfer function which
assumed similar baseline characteristics for its subjects
[45-47]. To date, only central aortic systolic pressure has
been shown to have excellent correlation and agreement
with direct measurement of aortic root pressure during
cardiac catheterization[30]. Secondly, inadequate adjust-
ment for factors that affect central aortic pressures may
possibly invalidate the reported difference as observed
between pre-eclampsia, gestational hypertension and
normal pregnancies [39-41,43]. Lastly, as most measures
were taken at one singular event at 2nd trimester on-
wards, the onset and magnitude of insult i.e. endothelial
dysfunction leading to arterial stiffness is uncertain.
Therefore, the rationale of the study aim is to system-
atically measure changes in central aortic stiffness and
associated factors beginning from first trimester onwardsto account for gestation specific physiological changes as
well as for alterations in environmental exposures and
shifts in the mental and emotional states of pregnant
women, prior to the development of gestational hyper-
tension or pre-eclampsia. Secondly, central aortic pulse
pressure is used as a measure of central aortic stiffness
instead of central augmentation index, as it is a direct
derivation from the difference between central aortic
systolic and diastolic pressures, without the assumptions
of a generalized transfer function as applied to the cen-
tral aortic augmentation index.
The cohort design will resolve issues associated with
temporality as reported in most studies using cross sec-
tional evaluation. However, losses to follow-up may poten-
tially introduce attrition bias into the study. Therefore
retention of study participants will be important and this
may be achieved through rapport building and close com-
munication with the study participants. Selection bias may
occur due to the convenient sampling technique and an
analysis on the socio-economic variables of women who
refused study participation to evaluate the occurrence of
selection bias will be done.
In conclusion, as raised arterial pressure is a manifest-
ation endothelial dysfunction, targeted measurement of
central aortic pressures in this study may yield important
information how these aberrant responses occur and its
role early detection and prediction of hypertensive disor-
ders in pregnancy.
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